samedan logo
 
 
 
spacer
home > ebr > autumn 2002 > editor's letter
PUBLICATIONS
European Biopharmaceutical Review

Editor's Letter

Times are not just tough, they have changed - a stark message but one interpretation of the environment that the European biotechnology sector faces today. As the chillier weather sets in and the hectic autumnal partnering season approaches, it will be interesting to hear whether some of the predictions and sentiments voiced within this issue receive further air time on the partnering conference stage. By volume of companies and people employed, as well as private equity investment, the European sector continues to grow strongly as reflected in DeLoitte & Touche's recently launched annual Mediscience Report, reviewed in this issue. However, the majority of this growth is within established companies, trying to progress technologies towards products and build value and sustainable critical mass 'until' the IPO window opens again. Therein seems to lie perhaps the more fundamental environmental change as institutional investors continue to show less than a glimmer of interest in biotechnology stocks.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Helen Abbott, Senior Consultant at Technomark Consulting Services
spacer
Dr Helen Abbott
spacer
spacer
spacer
Deirdre Ruane
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Ubiquigent celebrates milestone anniversary of DUBprofiler™ compound profiling platform

 Dundee, UK, 14th December 2021 – Today, Ubiquigent Limited (Ubiquigent) celebrates the 10th anniversary of its DUBprofiler™ compound profiling platform, together with KSQ Therapeutics joining its expanding customer base.
More info >>

White Papers

The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing

GE Healthcare Life Sciences

For the past several years, the biopharma industry has been buffeted by dynamic market conditions that are rapidly reshaping manufacturing requirements. These factors include: • The rise of small-market pharmaceuticals that do not require the production scale of the previous “blockbuster” drug model • Increased titers and process productivity that generate more bulk-product within a much smaller manufacturing footprint • The emergence of biosimilars and continued evolution of healthcare reform, which will increasingly pressure drug pricing and require greater cost discipline • Greater competition and shorter patent protection timelines, which will further ratchet up time-to-market pressures • Tighter capital markets that will create heightened scrutiny for all new investment projects
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement